Myovant Sciences to Present New Data on Relugolix in Prostate Cancer at American Society of Clinical Oncology (ASCO) 2020 Ann...
May 14 2020 - 08:30AM
Myovant Sciences (NYSE: MYOV), a healthcare company focused on
redefining care for women and for men, today announced that it
will present new efficacy and cardiovascular safety data from the
Phase 3 HERO study of once-daily, oral relugolix (120 mg) in men
with advanced prostate cancer at the American Society of Clinical
Oncology (ASCO)’s upcoming ASCO20 Virtual Scientific Program, to be
held May 29-31, 2020.
The new data will be presented by Neal Shore, M.D., medical
director of the Carolina Urologic Research Center and HERO program
steering committee member. Dr. Shore’s presentation (#5602), titled
“HERO phase III trial: Results comparing relugolix, an oral GnRH
receptor antagonist, versus leuprolide acetate for advanced
prostate cancer” will be included in the oral abstract session,
“Genitourinary Cancer—Prostate, Testicular, and Penile,” which will
be available for on-demand viewing starting at 8:00 a.m. Eastern
Time / 5:00 a.m. Pacific Time on Friday, May 29, 2020.
In April 2020, Myovant submitted a New Drug Application (NDA) to
the U.S. Food and Drug Administration for relugolix as a potential
treatment for men with advanced prostate cancer. The NDA is
supported by positive results from the Phase 3 HERO study, a
randomized pivotal study comparing relugolix versus leuprolide
acetate.
About Myovant SciencesMyovant
Sciences aspires to be the leading healthcare company focused
on redefining care for women and for men. The company’s lead
product candidate is relugolix, a once-daily, oral GnRH receptor
antagonist. The company has three late-stage clinical programs
for relugolix in uterine fibroids, endometriosis, and prostate
cancer. The company is also developing MVT-602, an oligopeptide
kisspeptin-1 receptor agonist, that has completed a Phase 2a study
for the treatment of female infertility as part of assisted
reproduction. Takeda Pharmaceuticals International AG, a
subsidiary of Takeda Pharmaceutical Company Limited, the originator
of relugolix, previously granted the company a worldwide
license to develop and commercialize relugolix
(excluding Japan and certain other Asian countries) and
an exclusive license to develop and commercialize MVT-602 in all
countries worldwide. Sumitovant Biopharma, Ltd., a wholly
owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is the
majority shareholder of Myovant. For more information, please
visit the company’s website at www.myovant.com.
Follow @Myovant on Twitter and LinkedIn.
Investor Contact: Frank Karbe President and
Chief Financial Officer Myovant Sciences, Inc.
investors@myovant.com
Media Contact: Albert Liao Director,
Corporate Communications Myovant Sciences, Inc.
media@myovant.com
Myovant Sciences (NYSE:MYOV)
Historical Stock Chart
From Feb 2024 to Mar 2024
Myovant Sciences (NYSE:MYOV)
Historical Stock Chart
From Mar 2023 to Mar 2024